SCHEMBL4106567

SCHEMBL4106567

CCCOc1ccc(NC(=O)Nc2ccc(F)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 6/20 0.68
▸ EPHX2 P34913 1/20 0.59
▸ CA12 O43570 2/20 0.58
▸ CA1 P00915 2/20 0.58
▸ CA2 P00918 2/20 0.58
▸ CA9 Q16790 2/20 0.58
▸ HRH3 Q9Y5N1 3/20 0.57
▸ MAPT P10636 5/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ CASP3 P42574 1/20 0.56
▸ TRPV1 Q8NER1 1/20 0.56
▸ SENP7 Q9BQF6 1/20 0.56
▸ HTT P42858 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113061 0.87 MAPT (0.73) FAAHMAPTMEN1KMT2ACASP3
SCHEMBL4106089 0.86 MEN1 (0.60) FAAHEPHX2HRH3MAPTMEN1
SCHEMBL4104949 0.86 PPARA (0.68) FAAHEPHX2CA12CA1CA2
SCHEMBL4124890 0.86 EPHX2 (0.60) FAAHEPHX2CA12CA1CA2
SCHEMBL4113295 0.86 RAB9A (0.71) FAAHEPHX2CA12CA1CA2
SCHEMBL4115767 0.85 MAPT (0.56) FAAHEPHX2CA12CA1CA2
SCHEMBL4112277 0.84 HRH3 (0.72) FAAHEPHX2CA12CA1CA2
SCHEMBL4113719 0.84 EPHX2 (0.59) FAAHEPHX2CA12CA1CA2
SCHEMBL4113500 0.84 EPHX2 (0.58) FAAHEPHX2CA12CA1CA2
SCHEMBL4117377 0.84 EPHX2 (0.71) FAAHEPHX2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 — — EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 — — WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 FAAH 4/4885EPHX2 2394/4885CA12 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback